{"id":"granulated-mesalamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL704","moleculeType":"Small molecule","molecularWeight":"153.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalamine (5-aminosalicylic acid) works primarily through local anti-inflammatory effects in the gastrointestinal tract. It inhibits the production of inflammatory mediators including prostaglandins and leukotrienes, and may also have immunomodulatory effects. The granulated formulation allows for targeted delivery to the colon where it exerts its therapeutic effect.","oneSentence":"Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:14.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction and maintenance of remission)"},{"name":"Crohn's disease (colonic involvement)"}]},"trialDetails":[{"nctId":"NCT00767728","phase":"PHASE3","title":"Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-12","conditions":"Ulcerative Colitis","enrollment":256},{"nctId":"NCT00744016","phase":"PHASE3","title":"Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-12","conditions":"Ulcerative Colitis","enrollment":305}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mesalamine pellets"],"phase":"phase_3","status":"active","brandName":"Granulated mesalamine","genericName":"Granulated mesalamine","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (colonic involvement).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}